January 8, 2021

Announcements

Melanie Lynch, MD, Appointed Director of Breast Surgery in Fairfield County

I am pleased to welcome Melanie Lynch, MD, FACS, Assistant Professor of Surgery (Oncology) and Director of Breast Surgery at Smilow Cancer Hospital Bridgeport, Fairfield, and Trumbull offices and the Norma Pfriem Breast Center. Dr. Lynch is a board certified General Surgeon and fellowship trained Surgical Oncologist. She previously served as Medical Director of the Summa Health System Breast Program and was Section Chief of General Surgery at Cleveland VA Medical Center. In addition, she held an appointment as Assistant Professor of Surgery and Associate Program Director of General Surgery Residency Program at Case Western Reserve University.

Dr. Lynch has significant clinical experience in breast cancer surgery, with a practice dedicated to the integration of oncoplastic techniques including nipple sparing mastectomy, oncoplastic approaches to breast conservation, and surgical techniques for the prevention of lymphedema. Recognizing the importance of multidisciplinary and patient centered care, she has developed innovative clinical programs, including multidisciplinary clinics for newly diagnosed breast cancer patients, a high-risk program for screening and management of women at increased risk of breast cancer, survivorship care, and use of integrative medicine for management of symptoms related to cancer treatment. Dr. Lynch was awarded the Crain’s Cleveland Business Physician Innovator Award in 2018 for the implementation of an access program that ensures next day access and expedited biopsies for women with a concern of cancer.

Smilow Nurses Celebrated

from the desk of
Charles S. Fuchs, MD, MPH
Director, Yale Cancer Center
and Physician-in-Chief
Smilow Cancer Hospital

Yale NewHaven Health
Smilow Cancer Hospital

News Center

Smilow Cancer Hospital and Yale Cancer Center: Always Remain

Watch Video

Yale Study Leads to FDA Approval of Drug to Treat Non-small Cell Lung Cancer
Earlier this week, the leadership of Smilow Cancer Hospital gathered virtually to recognize the outstanding efforts of our oncology nursing team in a belated Oncology Nursing celebration and to recognize the outstanding efforts of 14 of our team members with scholarship awards. The dedication and selflessness of the entire oncology nursing team was heralded by both Dr. Fuchs and Kim Slusser, who Dr. Fuchs praised for her continued calm, caring response, dedication, and intelligence.

Special thanks to Lisa Barbarotta and Tracy Carafeno, sponsors of the program; Sarah Infantino and Sandy Morgan, co-chairs; and Felicia Corolla and J.C. Carley, administrative liaisons.

The following awards were presented at the awards ceremony:

**First Annual Fredrick A. DeLuca Foundation Smilow Cares Scholarship Awards for RNs:**
- Kelly Baran
- Brianna Lutz
- Liana Braga
- Bethany Larkin
- Mario Lupone

**First Annual Fredrick A. DeLuca Foundation Smilow Cares Scholarship Awards for PCAs and ACAs:**
- Denali MacMath
- Nicole Myer
- Hope Serra
- Wendy Marin
- Eileen Sullivan

**Fredrick A. DeLuca Foundation Education Scholarship:**
- Nicholas Daniels
- Jessica Simoes

**11th Annual Oncology/Research Nursing Award:**
- Sunshine Sousa

**9th Annual Oncology/Research Patient Care Associate (PCA) / Ambulatory Care Associate (ACA) Educational Grant:**
- Danielle Welz

### Celebrating the 44-Year Career of Dr. Joseph Piepmeier

It is with mixed emotions that we announce the retirement of Joseph Piepmeier, MD, Nixdorff-German Professor of Neurosurgery, and his transition to emeritus status. His retirement marks a bookend in an illustrious 44-year career at Yale School of Medicine, where he served as section chief for surgical neuro-oncology and cared for on thousands of

In a recent presentation, Akiko Iwasaki, PhD, Waldemar Von Zedwitz Professor of Immunobiology and Molecular, Cellular and Developmental Biology, talks about COVID-19 and the response of the body's immune system when an individual is first infected, and how the immune system responds to reinfections.

Tune in to Yale Cancer Answers for a discussion on Menopause and Cancer for both cancer survivors and patients with Mary Jane Minkin, MD. Dr. Minkin is the co-founder of the Smilow Cancer Hospital Sexuality, Menopause, and Intimacy Clinic, which is available to all women looking for support.
patients. During this time, he has also served as editor-in-chief of the Journal of Neuro-Oncology and president of the Joint Section on Tumors of the American Association of Neurological Surgeons(AANS)/Congress of Neurological Surgeons(CNS). He was a sought-after international lecturer on neuro-oncology and also served as the president of the Neurosurgical Society of America and the Connecticut Neurosurgical Society.

Joe helped establish and expand the Brain Tumor Center at Smilow Cancer Hospital to facilitate multidisciplinary management for patients with brain tumors. He collaborated with Mark Saltzman, PhD, and Jiangbing Zhou, PhD, on groundbreaking work to develop a novel drug delivery mechanism utilizing biodegradable nanoparticles. In addition, he worked closely with the late Anthony van den Pol, PhD, to facilitate developing oncolytic viruses to attack malignant gliomas. Joe received the Bittner Award from the AANS for his research and the Lifetime Achievement Award from CNS.

Please join me in thanking Joe for his dedication to Yale Cancer Center and Smilow Cancer Hospital and wishing him well during his retirement.

CME Series Launch
Please join us for Upcoming CME Programs from Yale New Haven Digestive Health, Smilow Cancer Hospital’s Liver Cancer Program, and Yale Hematology. Each program is free to attend, with advance registration.

Notables

Sajid Khan, MD, Associate Professor of Surgery (Oncology), has been awarded the Bridgeport Hospital Platinum Quality Award in recognition of the time, hard work, and dedication placed into caring for our patients.

Joseph Vinetz, MD, Professor of Medicine (Infectious Diseases), and Geoffrey Chupp, MD, Professor of Medicine (Pulmonary), have been awarded the 2020 Ken Griffin-Prostate Cancer Foundation Special Challenge Award to support their research to test the efficacy of camostat, a TMPRSS2 inhibitor, on preventing prostate cancer progression and poor outcomes in patients who recently tested positive for SARS-CoV2 infection.

Read More

The COVID-19 pandemic forced cancellation of the 10th annual Beach Jam for Breast Cancer at the Westbrook Elks Lodge in August. Proceeds from this popular event are directed to breast cancer patient assistance at Smilow Cancer Hospital. Regardless of this year’s challenges, the Westbrook Elks held a fundraiser with their members and raised $5,000 for breast cancer patients. Pictured (l to r) Joe Carpio, Westbrook Elks Lodge Exalted Ruler, Jim Pino of the band Freeplay, and Beach Jam co-chair Nancy Malafronte present the proceeds to Kevin Walsh, VP, YNHH Development Office, at Shoreline Medical Center in Guilford. Thank you Westbrook Elks and Freeplay!

Read More

Smilow Cancer Hospital physicians and staff are rolling up their sleeves and leading by example, joining the thousands of Yale New Haven Health and Yale School of Medicine physicians and staff who have already received the COVID-19 vaccine.
Congratulations to Pamela Fitzgerald MSW, Oncology Patient Navigator, Rachel Abraham MSW, Oncology Patient Navigator, and Michael Cohenuram, MD, from the Smilow Cancer Hospital Care Center in Trumbull who were presented with the Bridgeport Hospital’s Gold Quality Award in December. They were nominated by Marissa Lavin, APRN, who wrote about their collective care for a palliative care patient. Marissa wrote: “The love and attentiveness that was shown to a patient who suffered from a complex social situation, and whose care was managed by the Palliative Care Team for years. Thank you for your empathy, support and for having such a positive impact on this patient’s life. You provided the highest quality of care and helped the patient transition to the last chapter of her life with peace and dignity.”

Center for Community Engagement and Health Equity

Are you looking for a community perspective to inform and enrich your research?

The YCC Center for Community Engagement and Health Equity (CEHE) in partnership with the Community Alliance for Research and Engagement (CARE) is looking to pair its Community Research Fellows with YCC research teams to bring community perspectives to cancer research.

We are supporting a fellowship program for diverse New Haven residents to work in collaboration with investigators on cancer research projects. Community Research Fellows will begin training in January 2021 on Patient-Centered Outcomes Research (PCOR), Community-Based Participatory Research (CBPR), cancer health disparities in New Haven, and broader social determinants of health. Fellows will be placed in pairs and embedded with selected YCC-affiliated research groups/laboratories from January to September of 2021 to consult and contribute to research projects.

Paired with researchers, Community Research Fellows may contribute to ongoing research projects in the following ways:

- Contribute to the design of research materials, such as survey questions, focus groups, data collection protocols, recruitment and community outreach strategies, and data interpretation.
- Help disseminate research findings and work with the community to identify research priorities.
- Facilitate and develop authentic connections within the New Haven community.

Community Research Fellows will dedicate approximately five hours per week throughout the 9-month program, working as member of

We wish you all a happy and safe New Year, and thank you for your continued support of our teams at Smilow Cancer Hospital and Yale Cancer Center! Together, we have renewed hope and for 2021. #crushcovid

Read More

On a daily basis, physicians and staff at the Smilow Cancer Hospital Care Center in Greenwich comment on how thankful and lucky they are to be working with Elizabeth Gineo, RN, Nursing Professional Development Specialist. Liz supports the entire clinical team including ACAs, practice nurses, infusion nurses, RNCs, and physicians to ensure a safe, effective, and efficient environment of care for our patients in Greenwich. She assists with IV insertion and verifying chemotherapy orders, all while observing and educating. Liz is the go-to person with any questions on documentation issues or with EPIC, and addresses problems head on. Always willing to take initiative and jump in when needed, Liz is a #SmilowStar!

Liz is pictured here participating in the Smilow Cancer Hospital Closer to Free Spin Event at Greenwich Hospital in September.

HealthExperiencesUSA, a national network that strives to bring diverse patient voices to American
research teams and receiving monthly training and support sessions through CARE/CEHE.

If you have a project/study that would benefit from a community perspective, please contact Erin Singleton, Program Manager of CEHE.

Employee Profile: Alexis Glazewski, RN

Working in end-of-life care is an intensely emotional and intimate experience. For Alexis Glazewski, RN, a pediatric nurse who was transferred to the COVID-19 comfort measures-only (CMO) unit at Smilow Cancer Hospital, she has thrived working with this special population of patients – and their families.

“In college, I had a clinical in a hospice setting and loved it,” said Alexis. “It was one of the experiences that instantly felt right for me, and it has been an honor working on the Supportive Care Unit (SCU) since April. It is a privilege to serve these patients and their families as their nurse for a large number of reasons, including getting to always make sure these patients are treated as human beings with a story. This allows me to use a holistic approach and utilize music, stories, and more to create the most comforting environment. Creating a connection and being able to hold their hand while they are passing and crossing that bridge comfortably is a gift.”

Alexis provides support to the grateful families, and helps coordinate the rotation of visitors given the current restrictions due to COVID-19. While patients who enter this unit generally have anywhere from six months to a matter of days left to live, Alexis says it is not always a sad transition for them; most are able to find peace and enjoy sharing stories of their life experiences with her.

Brianna Lutz, BSN, RN, OCN, Assistant Patient Services Manager, says of Alexis and her work in the SCU, “She made the unit the special place that it was. She hand-drew individualized patient signs for each of the doors. While the unit was largely supported by the nursing resource pool, Alexis created tips and tricks for all nurses to reference during their shifts. She planned final birthday parties for patients, took them to the healing garden, and came in on her days off to comfort patients’ loved ones. Alexis truly became the backbone of the unit and took initiative to problem solve and advocate for changes that would benefit the patients.”

Brianna continues, “Alexis is an irreplaceable nurse. It is impossible to adequately capture her genuine spirit and dedication to her patients.
and their families. She shows incredible resiliency, coming to work each day with a smile and positivity. Her compassion and empathy is second to none and we are all extremely grateful for her commitment to touching patients at end of life. Alexis has demonstrated grace in all aspects of her care and embodies the ‘I am YNHH’ model.”

Recent Publications

Covid-19 and Value Based Health Care - Never Let a Serious Crisis go to Waste
Mario Strazzabosco MD, PhD
EASL International Liver Foundation
Read More

Aging with HIV in Latin America and the Caribbean: a Systematic Review
Current HIV/AIDS Reports, Online ahead of print.
Read More

Dairy Intake During Adolescence and Risk of Colorectal Adenoma Later in Life
British Journal of Cancer, Online ahead of print.
Read More

Chow RD, Majety M, Chen S (2021)
The Aging Transcriptome and Cellular Landscape of the Human Lung in Relation to SARS-CoV-2
Nature Communications.
Read More

Shallis RM, Podoltsev NA (2020)
Maintenance Therapy for Acute Myeloid Leukemia: Sustaining the Pursuit for Sustained Remission
Current Opinion in Hematology, Online ahead of print.
Read More

End-of-life Patterns of Symptom Management and Cancer-directed Care among Medicare Beneficiaries with Lung Cancer: a Claims-based Analysis
Supportive Care in Cancer, Online ahead of print.
Read More

Network Machine Learning Maps Phytochemically Rich "Hyperfoods" to Fight COVID-19
Human Genomics.

“Osimertinib has demonstrated an unprecedented disease-free survival (DFS) benefit for early-stage lung cancer patients with EGFR mutations who face high rates of recurrence even after surgery and chemotherapy,” said Roy S. Herbst, MD, PhD, chief of medical oncology at Yale Cancer Center and Smilow Cancer Hospital and principal investigator of the ADAURA trial. “This approval will now provide a much-needed treatment option for patients battling this difficult to treat lung cancer.”

Follow Yale Cancer Center on Twitter

Follow us on Twitter

Thank you to Dr. Markus Müschen for presenting @YaleCancer virtual Grand Rounds highlighting his B-cell and #leukemia research and the Frisbee Family for supporting the Richard Frisbee Memorial Lecture.

@VirusesImmunity Dr. Akiko Iwasaki talked to @VuMedi about the odds of getting #COVID19 twice and if the severity of illness will be milder.

@TaraSanftMD joined a panel of experts to write a new @NCCN resource to guide #cancer survivors after diagnosis and treatment.

Join us at noon today for @YaleCancer virtual Grand Rounds/Frisbee Lecture. Dr. Markus Müschen presents "Mechanism of B-cell Selection as Therapeutic Targets."

An article including study results by @DrRoyHerbstYale showing #osimertinib


*Expert Opinion on Biological Therapy*, Online ahead of print.

Read More

Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer by Pattern of Metastatic Spread: ARCHES Post Hoc Analyses

Read More

Hooley R, Butler R (2020)
Digital Breast Tomosynthesis May Not Provide Optimal Surveillance of Breast Cancer Survivors
*Radiology*, Online ahead of print.

Read More

Savic LJ, Schobert IT, Hamm CA, Adam LC, Hyder F, Coman D (2020)
A High-throughput Imaging Platform to Characterize Extracellular pH in Organotypic Three-dimensional In Vitro Models of Liver Cancer
*NMR in Biomedicine*, Online ahead of print.

Read More

Cmelak A, Dietrich MS, Li S, Ridner S, Forastiere A, Burtness BA, Cella D, Murphy BA (2020)
ECOG-ACRIN 2399: Analysis of Patient Related Outcomes after Chemoradiation for Locally Advanced Head and Neck Cancer
*Cancers of the Head and Neck.*

Read More

A Phase 1b Expansion Study of TAS-102 with Oxaliplatin for Refractory Metastatic Colorectal Cancer
*Cancer*, Online ahead of print.

Read More

Impact of Cavity Shave Margins on Margin Status in Patients with Pure Ductal Carcinoma in Situ
*Journal of the American College of Surgeons*, Online ahead of print.

Read More


Calendar

**Intersections Science Fellows Symposium**
January 6-8; All Day
Nancy J. Brown, MD | Darin Lattimore, MD | Gary Hunnicutt | Joan Stetz, PhD | Martha Munoz | Antonio Giraldes, PhD | Daniel Alfonso Colon-Ramos, PhD | Monkol Lek, PhD | Holden Thorp | Kizzmekia Corbett | Kafui Dzirasa

Learn More

**Yale Cancer Answers**
January 10; 7:30 PM
NPR
*Role of Surgery in High-risk Ovarian Cancer*
Mitchell Clark, MD

Learn More

**Radiobiology and Radiotherapy Research Program**
January 11; 11:00 AM
*Hypoxia Promotes EGFR Inhibitor Resistance in Lung Cancer Cells via Multiple Mechanisms*
Yuhong Lu, PhD, MD

Learn More

**Yale Cancer Center Grand Rounds**
January 12; 12:00 PM
Edward Snyder, MD and Suchitra Krishnan-Sarin, PhD

Learn More

**CB Seminar Series**
January 12; 1:00 PM
*Nuclear Mechanotransduction: Regulation of Cell Fate and Integrity*
Sara Wickström MD, PhD

Learn More

**Pulmonary, Critical Care and Sleep Medicine Grand Rounds**
January 13; 3:00 PM
*COVID-19 and Coagulopathy*
Alfred Lee, MD, PhD

Learn More

**Pathology Grand Rounds**
January 14, 12:30 PM
*NGS-based Spatial Omics Profiling of Tissues*
Rong Fan, PhD

Learn More

**Yale Cancer Center Seminar**
January 14; 4:15 PM
*NET Work: Connecting the Dots to Improve the Lives of Patients with Neuroendocrine Neoplasms*
A Case of Acute Myeloid Leukemia with Unusual Germline CEBPA Mutation: Lessons Learned about Mutation Detection, location, and Penetrance

*Leukemia and Lymphoma*, Online ahead of print.

Read More


A Complex Karyotype and a Genetic Mutation in Acute Myeloid Leukaemia

*The Lancet.*

Read More

**Funding and Award Opportunities**

**NCI Cancer Clinical Investigator Team Leadership Award (CCITLA) P30 Administrative Supplement for Fiscal Year (FY) 2021**

This award recognizes and supports outstanding clinical investigators who enable their cancer center’s NCI-funded clinical trials enterprise.

**Application Deadline:** January 11, 2021

Read More

The American Head and Neck Society will sponsor nine research grants for 2021 which are available through American Academy of Otolaryngology CORE.

- AHNS/AAO-HNSF Young Investigator Combined Award
- AHNS/AAO-HNSF Translational Innovator Award
- AHNS Pilot Grant
- AHNS Ballantyne Resident Research Pilot Grant
- AHNS Endocrine Surgery Section Eisai Research Award
- AHNS Endocrine Surgery Section Stryker Research Grant
- AHNS Presidential Request for Application Pilot Award on Mucosal Head and Neck Cancer Research
- AHNS Presidential Request for Application Pilot Award on Salivary Gland Cancer Research
- AHNS Presidential Request for Application Pilot Award on Basic and Translational Research

**Full Application Deadline:** January 15, 2021

Read More

**Collaborative Approaches to Engineer Biology for Cancer Applications (U01)**

This FOA invites applications to develop and apply innovative synthetic biology approaches to address challenges across the spectrum of cancer research.

**Application Deadline:** January 15, 2021

Read More

**RFI Regarding Opportunities for New National Programs at the NCI's Frederick National Laboratory for Cancer Research**

The purpose of this RFI is to seek input from members of the cancer research community on the most important needs and promising opportunities in cancer research that are difficult to address on an individual scale.

**Submission Deadline:** January 18, 2021

Read More

https://app.constantcontact.com/pages/campaigns/email-details/details/activity/7c7d9380-307c-4539-9848-8e241da8a7f4
NCCN Request for Proposals (RFP): Phase I/II Clinical and Correlative/Preclinical Trials of Decitabine and Cedazuridine for Hematologic Malignancies and Solid Tumors
This RFP, made possible by a research grant from Taiho Oncology, Inc., is to support NCCN Member Institution faculty for the performance of clinical and correlative studies of decitabine and cedazuridine (DEC-C) in the treatment of hematologic malignancies and solid tumors.
Application Deadline: January 19, 2021
Read More

Cancer Intervention and Surveillance Modeling Network (CISNET) Incubator Program for New Cancer Sites (U01)
The overarching goal of this FOA is to expand comparative simulation modeling approaches developed by CISNET to new cancer organ sites beyond the sites which have been previously funded (breast, colorectal, prostate, lung, esophageal, and cervical) under CISNET.
Application Deadline: January 20, 2021
Read More

Specialized Programs of Research Excellence (SPOREs) in Human Cancers for Years 2021, 2022, and 2023 (P50)
Through this FOA, the NCI and National Institute of Dental and Craniofacial Research (NIDCR) invite applications for P50 Research Center Grants for Specialized Programs of Research Excellence (SPORE)
Application Deadline: January 25, 2021
Read More

Cancer Research Education Grants Program
The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of the NCI R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs.
- Curriculum or Methods Development (R25 Clinical Trial Not Allowed) Read More
- Courses for Skills Development (R25 Clinical Trial Not Allowed) Read More
- Research Experiences (R25 Clinical Trial Not Allowed) Read More
Due Dates: January 25, 2021

2021 Packard Fellowships in Science and Engineering Program
A highly prestigious and competitive program that recognizes future leaders in the disciplines of physics, chemistry, mathematics, biology, astronomy, computer science, earth science, ocean science, and all branches of engineering
Application Deadline: January 28, 2021
Read More

Through this FOA, the NCI and NIEHS invite applications to support innovative scientific research in new prospective cohorts that

Submissions
Please submit your recent publications, awards, and grant announcements to:
Renee Gaudette
Director, Public Affairs and Communications
addresses knowledge gaps in cancer etiology and carcinogenesis processes with a focus on environmental exposures.

**Application Deadline:** January 29, 2021

**DeLuca Awards**
The DeLuca Center for Innovation in Hematology Research was formed thanks to a generous donation by the Fredrick A. DeLuca Foundation. Each year a total of 5 Pilot Awards and 1 Career Development Award will be awarded to investigators who are participating in hematologic based research.

**Pilot Award:** intended to support collaborative hematology based research.

**Application Deadline:** February 1, 2021

**Music and Health: Understanding And Developing Music Medicine (R01)**

**Application Deadline:** February 5, 2021

**Music and Health: Understanding And Developing Music Medicine (R21)**

**Application Deadline:** February 16, 2021

These FOAs are intended to: (1) increase our understanding of how music affects the brain when it is used therapeutically and/or (2) use that knowledge to better develop evidence-based music interventions to enhance health or treat specific diseases and disorders.

**Career Development Award:** intended to provide early career clinical or laboratory-based investigators in Hematology, the opportunity to focus on research to advance patient care, therapies, and outcomes.

**Letter of Intent Due:** March 1, 2021

**Utilizing In Vitro Functional Genomics Advances for Gene-Environment (G x E) Discovery and Validation (R01)**
The purpose of this FOA is to solicit applications that fully integrate recent innovative advances of in vitro functional genomics tools/technologies and approaches for environmental health and toxicology research. The overall goal of this NIEHS led initiative is to generate proof-of-principle studies incorporating these new in vitro approaches, together with well characterized exposures, to further our understanding of gene-environment (G x E) interactions in complex human disorders.

**Application Deadline:** February 1, 2021

**2021-2023 Clinical Investigator Award for Under-Represented Black, Indigenous, and People of Color (BIPOC) Surgeons**

This award is part of the SSO Diversity and Inclusion Advisory Board’s work to ensure inclusion of the brightest minds and keenest talents in
surgical oncology research. Applications are reviewed and selected by members of the SSO Research Committee.

**Application Deadline:** February 8, 2021

Read More

---

**Clinical Translation of Activated Optical Fluorescence Methods and Technologies for Sensitive Cancer Detection in Vivo (R01)**

The purpose of this FOA is to bring a highly sensitive imaging technology capable of detecting very small (1-3 mm³) tumors *in vivo* to clinical utility.

**Application Deadline:** February 10, 2021

Read More

---

**Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3)**

Through these FOAs, the NCI invites applications to support the validation of molecular/cellular/imaging markers and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of response or resistance to treatment, as well as markers for cancer prevention and control.

**Application Deadline:** February 18, 2021

Read More

---

**Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R21)**

This FOA solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies offering novel molecular or cellular analysis capabilities for basic or clinical cancer research.

**Application Deadline:** February 22, 2021

Read More

---

**Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33)**

This FOA invites grant applications proposing exploratory research projects focused on further development and validation of emerging technologies offering novel capabilities for targeting, probing, or assessing molecular and cellular features of cancer biology for basic or clinical cancer research.

**Application Deadline:** February 22, 2021

Read More

---

**Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R21)**

This FOA solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies that improve the quality of the samples used for cancer research or clinical care.

**Application Deadline:** February 22, 2021

Read More

---

**Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33)**
This FOA solicits grant applications proposing exploratory research projects focused on further development and validation of emerging technologies that improve the quality of the samples used for cancer research or clinical care.

**Application Deadline:** February 22, 2021

Read More

**NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00)**

The purpose of the NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Fellows (K99/R00) program is to increase and maintain a strong cohort of new and talented, NCI-supported, independent investigators. The objective of this award is to facilitate a timely transition of these fellows from their mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions.

**Application Deadline:** February 26, 2021

Read More

**NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00 - Independent Basic Experimental Studies with Humans Required)**

The purpose of the NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00) program is to increase and maintain a strong cohort of new and talented, NCI-supported, independent investigators. The program will provide independent NCI research support during this transition to help awardees to launch competitive, independent research careers.

**Application Deadline:** February 26, 2021

Read More

**JH Milstone Fund 2021**

This FOA supports early stage investigators and innovative research and education in thrombosis, thrombolysis and hemostasis. Proposals may focus on any aspect of thrombosis, thrombolysis and hemostasis – including biochemistry, genetics, clinical evaluation and testing, quality improvement and treatment. Please contact Richard Carr for more information.

**Letter of Intent Due:** March 1, 2021

Read More

**Social and Behavioral Intervention Research to Address Modifiable Risk Factors for Cancer in Rural Populations (R01)**

The purpose of this FOA is to solicit applications to develop, adapt, and test individual-, community- or multilevel interventions to address
modifiable risk factors for cancer in rural populations.

**Application Deadline:** March 15, 2021

Read More

**Cellular Cancer Biology Imaging Research (CCBIR) Program (U54)**
The NCI invites applications for Cellular Cancer Biology Imaging Research (CCBIR) Centers. The Centers will develop and test enabling imaging technologies at the cellular and organ scales driven by specific fundamental questions in cancer biology. The overall purpose of the CCBIR initiative is to facilitate innovation in advanced imaging technologies that could be applied to fundamental basic and pre-clinical research problems in cancer biology.

**Application Deadline:** March 18, 2021

Read More

**Cancer Grand Challenges Program**
The NCI and Cancer Research UK (CRUK) are partnering to fund the Cancer Grand Challenges program. Cancer Grand Challenges will fund novel ideas by multidisciplinary research teams from around the world that offer the potential to advance bold cancer research and improve outcomes for people affected by cancer. These nine challenges are aimed at solving complex problems in cancer research, which, if solved, could have a transformative impact towards progress.

**Application Deadline:** April 22, 2021

Read More